Evidence map›Paper›PMID 41362708›Full record

ArticleJHEP reports : innovation in hepatology2025

The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes.

Hiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara, Takahiro Tsuchiya, Makoto Fujiya, Midori Sawada, Ryo Izai, Teppei Akatsuka, Chihiro Miwa, Takuya Yonemoto and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Hiroaki KanzakiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takamasa IshinoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sadahisa OgasawaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takahiro TsuchiyaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Makoto FujiyaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Midori SawadaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ryo IzaiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Teppei AkatsukaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chihiro MiwaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takuya YonemotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sae YumitaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Miyuki NakagawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ryuta KojimaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keisuke KorokiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masanori InoueDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kazufumi KobayashiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naoya KanogawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masato NakamuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayuki KondoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shingo NakamotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tsukasa TakayashikiDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuka TakanoDepartment of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Kaho TakataDepartment of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Jason LinDivision of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
Masahito KawazuDivision of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
Jun-Ichiro IkedaDepartment of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masayuki OhtsukaDepartment of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yujin HoshidaDivision of Digestive and Liver Diseases, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Mina KomutaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yosuke TogashiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Marcel Bernard Mettlen · 2010 to 2026
$53.7M
UT Southwestern Liver Cancer SPOREP50CA295495 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Yujin Hoshida, Amit Singal · 2025 to 2026
$7.5M
Trial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6M
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Non-invasive etiology-adjusted precision liver cancer risk predictionR01CA292930 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2025 to 2025
$2.9M
Epigallocatechin gallate for prevention of lethal cirrhosis complicationsR01CA282178 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Yujin Hoshida, Amit Singal · 2023 to 2026
$1.8M
NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA295495NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS R01 CA282178NCI NIH HHS R01 CA292930
6 · The paper itself

Abstract

Background & Aims: Atezolizumab plus bevacizumab (Atez/Bev) improves prognosis in advanced hepatocellular carcinoma, but its mechanisms remain unclear. This study aims to identify predictive biomarkers through a comprehensive analysis of the tumor microenvironment. Methods: Biopsy samples from 94 patients with advanced hepatocellular carcinoma before Atez/Bev were analyzed using immunohistochemistry, bulk RNA-sequencing, flow cytometry, and multiplexed imaging. The tumor microenvironment assessment included profiling of CD8 Results: We found favorable progression-free survival to be associated with a high percentage of programmed death-1 (PD-1) positivity in CD8 Conclusions: We demonstrate that immunohistochemistry analysis to determine the localization and distribution of CD8 Impact and implications: This study demonstrates that the localization and distribution pattern of CD8 Clinical trials registration: The study protocol was registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (UMIN000047701).

Indexed as

atezolizumabbevacizumabhepatocellular carcinomaimmunotherapytumor-infiltrating lymphocytetumor microenvironment

Identifiers

PMID41362708
PMCPMC12682129

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.